Linker Information
General Information of This Linker
| Linker ID |
LIN0GUBTS
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
MC-β-Ala-(glucuronide)-PABC
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
|
|
||||||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
BA1302 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Inclusion criteria require histologically confirmed metastatic/unresectable solid tumors (Part A: any advanced solid tumors; Part B: specific cancers including melanoma, breast cancer, NSCLC, or pancreatic adenocarcinoma) with progression after standard therapy, ECOG ≤1, measurable disease by RECIST v1.1, and available tumor tissue for biomarker analysis. Exclusions comprise other active malignancies within 5 years (except certain cured cancers), recent anticancer treatments (≤28 days), severe drug hypersensitivity, pregnancy/lactation, or conditions compromising safety/study compliance.
Click to Show/Hide
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06596915 | Clinical Status | PHASE1 | ||
| Clinical Description |
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy of BA1302 in Patients With Advanced Solid Malignancies
|
||||
| Primary Endpoint |
The primary safety endpoints include the number of participants experiencing dose-limiting toxicities (DLTs) within the first 21 days and adverse events (AEs) recorded through 28 days after the last treatment.
|
||||
| Other Endpoint |
Key secondary endpoints focus on pharmacokinetics (AUC0-t, AUC0-inf, Cmax, t1/2, and AUC at steady state) and immunogenicity (ADA incidence), all evaluated over approximately one year. Efficacy measures comprise objective response rate (ORR) and duration of response (DOR) per RECIST v1.1.
|
||||